All In Biotech

Drug Trial Radar · NCT00473577

Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients

Two Phase, Open-Label, Sequential, Ascending Dose Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients

Last checked: Nov 19, 2026Latest source record: Aug 25, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Planned (sponsor's estimate)

Start

Aug 2005

Primary completion

Nov 2007

Study completion Dec 2007

Sponsor

Lead sponsor
Pharmacyclics LLC.AbbVie (ABBV)
Sponsor type
Industry
First posted
May 15, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

To determine the maximum tolerated dose (MTD) of CRA-024781 IV given by 2-hour intravenous infusions in patients with refractory solid or hematologic malignancies. To evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, and to evaluate bioavailability of CRA-024781 IV when administered in a single oral dose.

Conditions

  • Hematologic Neoplasms
  • Neoplasms

Interventions

  • CRA-24781Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Chicago

    Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.